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SUMMARY
Dense tissue infiltrates of IgG4+ plasma cells >50/high-powered field (HPF) are pur-
portedly highly specific for IgG4-related disease. However, the frequency and signifi-
cance of liver-infiltrating IgG4+ plasma cells in primary sclerosing cholangitis (PSC)
applying these cut-offs has not been determined. We sought to determine the inci-
dence of intrahepatic IgG4-positive staining in PSC patients undergoing transplanta-
tion, correlating findings with clinical parameters. Immunohistochemical staining
was performed on liver explants obtained between 1991 and 2009. Of 122 explants
obtained, hilar IgG4+ staining was found to be mild (10–29 IgG4+ cells/HPF) in
23.0%, moderate (30–50/HPF) in 9.0% and marked (>50/HPF) in 15.6%. Marked
hilar lymphoplasmacytic infiltration was significantly associated with marked hilar
IgG4+ staining (P < 0.001). No patient had marked peripheral IgG4+ staining,
although mild and moderate staining was observed in 24.5% and 3.3% respectively.
Marked hilar IgG4+ staining was significantly associated with the presence of domi-
nant biliary strictures (P = 0.01) and need for biliary stenting (P = 0.001). There did
not, however, exist any significant differences in the age at PSC diagnosis, presence
of inflammatory bowel disease or extrahepatic autoimmune disease, frequency of
cholangiocarcinoma, interval between diagnosis and transplantation, or post-trans-
plant PSC recurrence or survival. Of 51 control liver sections (PBC = 18; HCV = 19;
HBV = 8; AIH = 6), none had marked or moderate hilar IgG4+ staining, whereas
mild staining was seen in only 10% (P < 0.001). Marked (>50/HPF) hilar IgG4+
lymphoplasmacytic infiltration is frequently observed in PSC and associated with the
presence of dominant biliary strictures. However, unlike serum IgG4+, this does not
seemingly associate with clinical disease course.
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Primary sclerosing cholangitis (PSC) is a chronic progressive
disease of unknown aetiology characterized by fibrosclerotic
destruction of the bile ducts resulting in multifocal strictur-
ing of the biliary tree (Mendes & Lindor 2010; Hirschfield
et al. 2013). Orthoptic liver transplantation (OLT) currently
remains the only curative option; however, disease recur-
rence occurs in approximately 30% (Farges et al. 1995;
Solano et al. 2003; Maheshwari et al. 2004).
Immunoglobulin G4 (IgG4)-associated cholangitis (IAC)
often has similar cholangiographic features to PSC (Abdalian
& Heathcote 2006; Deheragoda et al. 2007; Umemura et al.
2007; Esposito et al. 2008; Webster et al. 2009; Culver &
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Bateman 2012) and sits within a broader family of IgG4-
related systemic disease of which autoimmune pancreatitis
(AIP) is the commonest manifestation (Stone et al. 2012).
Despite sharing many clinicopathological features with PSC,
an important distinction to recognize is that IAC is respon-
sive to treatment with corticosteroids (Bj€ornsson 2008) and
does not share such a strong association with inflammatory
bowel disease (IBD) (Ohara et al. 2012), although it has
recently been reported that intestinal mucosal IgG4+ plasma
cells are particularly increased in patients with colitis in the
context of PSC (Raina et al. 2013). An international consen-
sus group recently published their diagnostic criteria for IAC
incorporating similar histological, radiological, serological
and clinical findings to those found in the Mayo Clinic’s HI-
SORt criteria for AIP (Chari 2007; Ohara et al. 2012). Two
key diagnostic features of IAC are an elevated serum IgG4
level and the presence of tissue-infiltrating IgG4-positive
plasma cells on biopsy. However, ~10% of patients with PSC
are reported to have elevated serum IgG4 levels and thought
to represent a subpopulation with higher Mayo risk score,
higher serum ALP values, a greater propensity to develop
liver cirrhosis (Mendes et al. 2006) and reduced colectomy-
free survival (Navaneethan et al. 2013). Tissue-infiltrating
IgG4-positive plasma cell deposition has also been reported
in PSC liver, and in some studies, this has been proposed to
signify a more aggressive clinical course with shorter time to
transplantation and a higher likelihood of disease recurrence
(Zhang et al. 2010). However, the appropriate ‘cut-off’ point
used in differentiating true IgG4+-related cholangitis/pancrea-
titis from other pro-inflammatory conditions such as PSC is
unclear. According to the ‘Consensus Statement on the
Pathology of IgG4 disease,’ if a liver biopsy contains >10
IgG4-positive plasma cells per high-powered field (HPF) and
at least one histological feature (dense lymphoplasmacytic
infiltrate/storiform fibrosis/obliterative phlebitis), this finding
would be probable of IgG4-related disease (Deshpande et al.
2012), whereas the finding of >50 IgG4+ plasma cells/HPF
(Boston criteria) has been reported to have the highest speci-
ficity (Deshpande et al. 2012). Thus far, no study has
assessed the significance of finding liver-infiltrating IgG4+
plasma cells in PSC using the latter cut-off.
The primary aims of our study were to validate the preva-
lence of IgG4-positive plasmacytic tissue infiltration in
patients undergoing liver transplantation for PSC using the
revised Boston criteria and evaluate for any inherent pheno-
typic differences vs. those who stained IgG4-negative.
Materials and methods
A case series review was performed on all patients with PSC
undergoing liver transplantation at University Health Net-
work, Toronto, between 1991 and 2009. Explanted speci-
mens from unrelated aetiologies leading to chronic liver
disease were identified from our pathology database and
served as a comparator group. Institutional ethics approval
was obtained.
Clinical data
Clinical records were reviewed to establish the age at PSC
presentation, ductal phenotype (intrahepatic vs. combined
intra- and extrahepatic disease), presence of dominant stric-
tures – defined as stenosis of the common bile duct (CBD)
with a diameter ≤1.5 mm, or of the left or right hepatic duct
with a diameter ≤1 mm; time from PSC diagnosis to trans-
plantation, presence/phenotype of IBD, history of pancreati-
tis, evidence suggestive of extrahepatic IgG4-related diseases
or concomitant extra-hepatopancreatobiliary autoimmune
conditions, and/or the presence of clinically unsuspected,
incidental cholangiocarcinoma in the explant. Patient sur-
vival and evidence of recurrent PSC post-transplant were
also evaluated. Recurrent PSC was suspected based on
abnormal liver biochemistry post-transplant and confirmed
with diagnostic cholangiography. Allograft biopsy was per-
formed in cases of diagnostic uncertainty.
All patients undergoing transplantation were subject to full
clinical, laboratory and radiological assessment prior to the
procedure including a detailed clinical examination, labora-
tory work-up, cholangiogram and cross-sectional imaging.
On review, any individual with radiological and/or clinical
evidence suggestive of systemic extra-hepatopancreatobiliary
(HPB) manifestations of IgG4-related disease according to
HISORt criteria (Chari 2007) was excluded from the study.
Histopathology
Formalin-fixed, paraffin-embedded tissues sampling the liver
hilum were retrieved, and haematoxylin/eosin and Masson’s
trichrome staining performed on all sections. Given that per-
cutaneous liver biopsies routinely sample the peripheral liver
parenchyma, paired peripheral sections were also obtained
for analysis. All cases were reviewed by a histopathologist
with expertise in hepatobiliary disease blinded entirely to
clinical characteristics and patient outcome. Hilar lympho-
plasmacytic infiltration was characterized into three strata:
mild, moderate and severe (Figure 1). Briefly, mild infiltra-
tion was defined by scattered inflammatory aggregates with
few lymphocytes and plasma cells; moderate infiltration was
considered as such if dense focal lymphoplasmacytic aggre-
gates were identified in the hilum or around bile ducts;
severe infiltration was defined by the presence of a diffuse
and dense hilar collection of lymphocytes and plasma cells.
Immunohistochemistry
Specimens were immunohistochemically stained with anti-
IgG4 antibody (mouse monoclonal, Cat. No.: 05-30800,
clone HP6025; Life Technologies Inc., Burlington, ON,
Canada) at a dilution of 1:2000 (v/v) and one hour incuba-
tion. Briefly, 4-lm sections were dewaxed in five changes
of xylene and brought down to water through graded
alcohols. Pretreatment with 1% pepsin (P7125; Sigma-
Aldrich Canada Co., Oakville, ON, Canada) in 0.01 NaHCl
International Journal of Experimental Pathology, 2015, 95, 209–215
210 S. Fischer et al.
(pH 2.0) was performed for 15 min (37 °C), and endoge-
nous peroxidase blocked with 3% H2O2. The detection sys-
tem used was Biogenex Super-Sensitive Polymer Kit
(QD410-YAX) with colour development performed using
freshly prepared NovaRed (Cat. No. SK-4800; Vector
Laboratories Inc., Burlington, ON, Canada). Finally, sec-
tions were counterstained lightly with filtered Mayer’s hae-
matoxylin, dehydrated in alcohols, cleared in xylene and
mounted with Permount medium (Cat. No.: SP15-500;
Fisher Scientific Company, Ottawa, ON, Canada).
To quantify the degree of IgG4 positivity within any given
tissue section, the field containing the highest number of
IgG4+ cells was counted and polychotomized into 4 strata:
negative (<10 IgG4+ plasma cells/HPF), mild (10–29 cells/
HPF), moderate (30–50 cells/HPF) and marked (>50 cells/
HPF; Figure 2).
Statistical analysis
IgG4-positivity was correlated with the aforementioned clin-
ical parameters and degree of hilar lymphoplasmacytic
inflammation. Mann–Whitney-U nonparametric method was
used to determine whether significant differences existed
between groups. Differences in nominal data were compared
by chi-squared test or Fisher’s exact test when the number
was less than 5 in any given cell of a 2 9 2 table. The level
of significance was set at P < 0.05. Statistical analysis was
performed using SPSSV21.
(a) (b) (c)
Figure 1 Classification of severity of hilar lymphoplasmacytic inflammation. Sections of liver explants (hilum) with PSC showing
variable lymphoplasmacytic inflammation: (a) mild, (b) moderate, and (c) severe. (HE stain, 9100 magnification).
(a)
(b)
(c)
(d)
Figure 2 Stratification of IgG4+ immunostaining. IgG4 immunostaining of liver explants (hilum) with PSC showing: (a) focal
(negative) immunoreactivity, (b) mild immunoreactivity (c) moderate immunoreactivity, and (d) marked immunoreactivity (9400
magnification).
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Results
Patient characteristics
Over an 18-year period, 157 patients with PSC underwent
liver transplantation, of which explant tissue was readily
available in 122 cases (89 male). The median age of PSC
diagnosis was 36 years (range 10–67) with a median interval
from diagnosis to transplant of 6 years (8 months–24 years).
27.9% (n = 34) had only intrahepatic involvement, whereas
67.2% of patients (n = 82) had coexisting IBD, and 20.5%
(n = 25) a history of extra-hepatopancreatobiliary (HPB)
autoimmune disease. Of all patients transplanted, 5 (4.1%)
were diagnosed as having cholangiocarcinoma in-situ
(explant) and 13 (10.7%) developed evidence of recurrent
PSC.
The comparator group (n = 51) comprised 19 patients
transplanted for chronic viral hepatitis type C (HCV) infec-
tion, eight with chronic viral hepatitis B (HBV) infection, 18
with primary biliary cirrhosis (PBC; n = 18), and six trans-
planted for autoimmune hepatitis (AIH; n = 6).
The severity of hilar IgG4-positive immunostaining is
associated with the severity of hilar lymphoplasmacytic
infiltration in PSC
End-stage chronic biliary disease with dense periductal con-
centric fibrosis and ductopenia was confirmed in all PSC
cases undergoing transplantation. Of the 122 PSC explants
studied, 47.5% (n = 58) had positive IgG4 immunohisto-
chemical staining in the hilar tissue, of which 23.0%
(n = 28) had mild staining, 9.0% (n = 11) had moderate
staining and 15.6% (n = 19) had marked staining. Hilar
lymphoplasmacytic infiltration was marked in 52.9%
(n = 64), moderate in 28.1% (n = 34) and mild in 19.0%
(n = 23) of PSC patients. Neither storiform fibrosis nor sig-
nificant obliterative phlebitis [which are also characteristic
features of IAC (Ohara et al. 2012)] was identified in our
PSC cohort.
Patients with mild or moderate hilar lymphoplasmacytic
infiltration did not have statistically more positive staining
for IgG4 (P = 0.12), unlike patients with marked hilar lym-
phoplasmacytic infiltration, who were significantly more
likely to have positive immunohistochemical IgG4 staining
of any degree compared to those with lesser degrees of hilar
lymphoplasmacytic infiltration (OR: 15.6; 4.2–58.0,
P < 0.001). This retained significance when restricting the
analysis to those with >50 IgG4+ plasma cells/HPF (OR 6.0;
1.6–21.9, P < 0.001, Figure 3).
Only five non-PSC cases (3 HCV, 1 HBV, 1 PBC) had
positive hilar IgG4 immunohistochemical staining, and this
was of a mild degree only; no patient in the control group
was identified as having marked or moderate staining. The
frequency of hilar IgG4+ staining was significantly lower
compared to that found in PSC explants (P < 0.001).
The severity and pattern of hilar IgG4+ staining does not
correlate with that observed in peripheral liver
parenchyma in PSC
Thirty-four PSC patients (27.9%) also had positive IgG4
immunohistochemical staining in the peripheral liver paren-
chyma; 24.6% (n = 30) had mild staining and 3.3% (n = 4)
moderate staining. There was no significant association
between severities of peripheral IgG4 staining and hilar
IgG4 staining, neither did there exist an association between
the severity of hilar lymphoplasmacytic infiltration and the
severity of peripheral IgG4+ staining (data not shown). Four
patients (7.8%) in the comparator group (3 HCV, 1 PBC)
had evidence of peripheral IgG4+ staining (P < 0.001)
although this was of a mild degree only.
Patients with PSC and positive hilar IgG4+ staining are
more commonly men and have a previous history of
acute pancreatitis
In our PSC cohort, the presence of any hilar IgG4-positive
immunostaining (>10 1gG4+ plasma cells/HPF) was more
common in men (83.1% vs. 65.1% in the IgG4-negative
group; P = 0.04) and associated with a previous history of
acute pancreatitis (13% vs. 1.7%; P = 0.03). On retrospec-
tive evaluation, no radiological features indicative of AIP
were identified in this subgroup. On comparing with
patients who stained negative for IgG4, no statistically sig-
nificant differences existed with respect to age at PSC diag-
nosis, presence/phenotype of coexisting IBD or extrahepatic
autoimmune disease, ductal phenotype, frequency of cholan-
giocarcinoma, age at time of transplantation, interval
between PSC diagnosis and transplantation (Figure S1),
post-transplant PSC recurrence or post-transplant survival
(Table 1).
Figure 3 IgG4+ staining and degree of hilar lymphoplasmacytic
inflammation in explanted PSC liver tissue. Patients with
positive IgG4 immunohistochemical staining were significantly
more likely to have marked lymphoplasmacytic infiltration
(P < 0.001).
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Individuals with PSC and marked (>50/HPF) hilar
IgG4+ staining more frequently have a dominant
stricture
When restricting comparative analysis using the cut-offs pro-
vided by the recent Boston criteria for IgG4-associated sys-
temic disease, no significant gender differences were
observed between those with marked hilar IgG4+ staining
vs. those with <50 IgG4+ plasma cells/HPF (P = 0.25), and
despite a trend remaining with respect to previous episodes
of acute pancreatitis (P = 0.08), this failed to retain statisti-
cal significance. Perhaps most strikingly, patients with mod-
erate or marked hilar IgG4+ infiltration were significantly
more likely to have a dominant biliary stricture than those
with lesser degrees of IgG4+ infiltration (43.3% and 52.6%
vs. 24.3%; P = 0.04 and P = 0.01 respectively) and required
biliary stenting more commonly (43.3% and 57.9% vs.
21.3%; P = 0.02 and P = 0.001 respectively).
However, there was no significant difference in the fre-
quency of cholangiocarcinoma, median age at PSC diagno-
sis, median age at transplantation, pretransplant MELD
score, interval to transplantation following PSC diagnosis,
frequency/phenotype of coexisting IBD, incidence of post-
transplant PSC recurrence and all cause mortality after
transplantation between groups (Table 2).
Discussion
PSC is characterized histologically by chronic cholestasis,
inflammation and obliterative biliary fibrosis eventually
leading to cirrhosis. Presently, it is devoid of effective inter-
vention other than transplantation, and efforts continue to
rationalize pathophysiologic understanding with the goal of
identifying themes for intervention that account for patient
heterogeneity. The repeated observation of detecting ele-
vated serum IgG4 levels in a subgroup of PSC patients has
triggered interest in defining IgG4 contributions to disease
presentation as well as clinical outcome. In IAC and other
conditions falling under the ‘umbrella’ of IgG4-related sys-
temic disease, there exist key histopathological features
comprising recognized diagnostic criteria (Chari 2007;
Deshpande et al. 2012; Ohara et al. 2012), which are
Table 1 Hilar IgG4 immunohistochemical staining and clinical
characteristics
IgG4+
No. cases (%)*
IgG4
No. cases (%) P-value
Total 59 (48.4) 63 (51.6)
Male gender 49 (83.1) 41 (61.5) 0.04
History of acute
pancreatitis
7 (87.5) 1 (12.5) 0.03
Concomitant
autoimmune
disease†
13 (24.1) 12 (19.0) 0.07
History of IBD 40 (67.8) 42 (65.6) 0.95
Median age
(years) at PSC
diagnosis
36; range
16–67
39; range
13–63
0.23
Intrahepatic
ductal
involvement only
18 (31.0) 16 (25.0) 0.46
Dominant stricture 18 (31.0) 17 (26.6) 0.59
Previous biliary
stenting
20 (34.5) 13 (20.3) 0.08
Pretransplant
MELD score
14.6; range
9.2–26.7)
14.3; range
8.2–25.1
0.48
Cholangiocarcinoma‡ 2 (3.8) 3 (5.5) 1.00
Median age (years)
at transplant
40; range
18–61
44; range
21–66
0.15
Median time to
transplant (years)
after PSC diagnosis
6; range 0–24 6; range 0–22 0.40
PSC recurrence
after ransplant
8 (13.6) 5 (7.8) 0.46
All cause mortality
after transplant
13 (22.0) 14 (21.9) 0.84
*>10 IgG4+ plasma cells/high-powered field.
†Excluding inflammatory bowel disease (IBD).
‡Diagnosed on explant.
Table 2 Patients with marked hilar IgG4+ staining do not have a
different clinical phenotype to those with lesser degrees of
staining.
>50 IgG4+
plasma
cells/HPF
No. cases (%)
<50 IgG4+
plasma
cells/HPF
No. cases (%) P-value
Total 19 (15.6) 103 (84.4)
Male gender 16 (84.2) 73 (70.9) 0.25
History of acute
pancreatitis
3 (15.8) 5 (4.10) 0.08
Concomitant
autoimmune
disease*
2 (10.5) 23 (22.3) 0.05
History of IBD 16 (84.2) 65 (63.1) 0.08
Median age
(years) at PSC
diagnosis
37.5; range
11–68
37; range
10–63
0.93
Intrahepatic
ductal
involvement only
6 (31.6) 28 (27.2%) 0.71
Dominant stricture 10 (52.6) 25 (24.3) 0.01
Previous biliary
stenting
11 (57.9) 22 (21.4) 0.001
Pretransplant
MELD score
14.3; range
9.2–22.5
14.4; range
8.2–26.7
0.99
Cholangiocarcinoma† 0 (0.0) 5 (4.9%) 0.32
Median age (years)
at transplant
40.5; range
18–70
43; range
18–66
0.85
Median time (years)
to transplant after
PSC diagnosis
7; range 1–25 6; range
2–22
0.60
PSC recurrence
after transplant
3 (15.6%) 8 (7.8%) 0.27
All cause mortality
after transplant
3 (15.6%) 23 (22.3%) 0.84
*Excluding inflammatory bowel disease (IBD).
†Diagnosed on explant.
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distinct from changes observed in PSC. The morphological
appearances of IgG4-related disease, though highly charac-
teristic, require immunohistochemical confirmation with im-
munostaining of IgG4-bearing plasma cells, and although all
immunoglobulin subclasses may be represented within
involved tissue, IgG4 predominates the histological picture
yielding an increased IgG4:total IgG ratio. The optimal
value at which tissue-infiltrating IgG4+ staining differentiates
IgG4-related HPB disease from other diagnoses such as PSC
is heavily debated; however, the recent Boston criteria
suggest that >50 IgG4+ plasma cells/HPF is highly specific
for the former.
Herein, we illustrate that approximately half of all trans-
planted PSC patients have some evidence of hilar IgG4-posi-
tive staining in their explanted liver specimens. All patients
had developed end-stage chronic biliary disease as evidenced
by dense periductal concentric fibrosis, but without further
evidence to support a formal diagnosis of IAC. The PSC
group staining positive for hilar IgG4 plasma cells was more
likely to be men and have a prior history of acute pancreati-
tis. This is noteworthy given that IAC is also frequently
associated with AIP (Ohara et al. 2012), but also given our
recently published study showing that PSC patients with an
elevated serum IgG4 are also more often men with a previ-
ous episode of pancreatitis (Alswat et al. 2012). Our study
also represents one of the first attempts to address the signif-
icance of IgG4+ plasma cells in PSC liver whilst applying the
cut-offs deemed ‘highly specific’ used for diagnosing IAC as
provided by the Boston criteria. In doing so, we were able
to demonstrate that ~16% of PSC patients undergoing trans-
plantation have evidence of marked (>50/HPF) IgG4+ hilar
infiltration, a finding associated with the severity of hilar
lymphoplasmacytic inflammation. These results echo those
published by Zhang et al. (2010). Such patients were also
more likely to have developed dominant biliary strictures
and a need for subsequent biliary intervention, itself a risk
factor for developing acute pancreatitis. In diseases other
than PSC, IgG4+ staining was, however, much less apparent.
Zen et al. (2007) recently reported finding IgG4-positive
cellular staining in 29% of PSC liver explants and in keep-
ing with our observations found no appreciable differences
in the frequency of cholangiocarcinoma or coexisting auto-
immune disease, time to transplant, post-operative mortality
or disease recurrence rate post-transplant between IgG4-
positive and IgG4-negative PSC patients. We did, however,
observe a significant difference in the incidence of dominant
biliary strictures which may reflect the application of using
different cut-offs for defining IgG4-positive staining – ours
being the first to assess the implications of >50 IgG4+
plasma cells/HPF in PSC. Whether there is a continuum of
biliary disease with IAC and PSC belonging to the same
spectrum remains unclear. The significance of finding IgG4+
tissue staining in PSC patients may perhaps represent the
‘end result’ of a local immune reaction around injured bile
ducts in response to an as yet unidentified (auto)antigen, or
to some intrinsic or extrinsic substrate present in bile, and
offers a plausible explanation as to the observed association
with dominant biliary strictures. Of interest, it is notable
that a subset of patients with PSC and dominant biliary
strictures may respond to immunosuppressive therapy (Erke-
lens et al. 1999) and warrant further characterization with
respect to hilar IgG4+ status.
From a practical perspective, it is important to highlight
the lack of association between peripheral and hilar samples.
Although it is those with marked hilar lymphoplasmacytic
inflammation who are most likely to stain positive for IgG4+
plasma cells, we have shown that there is poor correlation
between hilar and peripheral IgG4-positive staining. This
implies that peripherally targeted liver biopsies may not be
particularly useful in terms of predicting whether a patient
may have IgG4-associated cholangitis. Given the infrequency
with which hilar biopsies are performed in routine practice,
attempting selection of PSC patients for potential therapeu-
tic trials of corticosteroid therapy, based on peripheral-tissue
IgG4 positivity alone, should be discouraged.
The main limitations from our report stem from an
absence of paired serum IgG4 readings. Given the retrospec-
tive nature of the study, the vast majority of included
patients were transplanted in an era during which IgG4-
related disease had yet to be recognized and whereby rou-
tine assessment of IgG4 was neither standard practice nor
advocated by international guidelines. Nevertheless, we have
recently reported on the frequency and clinical significance
of elevated serum IgG4 elsewhere (Alswat et al. 2012).
Moreover, Zhang et al. (2010), although using different cut-
offs for determining high IgG4-positive staining, did reveal a
positive correlation between serum IgG4 concentration and
degree of IgG4-positive cellular infiltrate in the explanted
livers of PSC patients, and there is merit in supporting a
prospective approach to sample acquisition and evaluation
in this regard. We were also unable to provide hilar IgG4/
total IgG ratios; thus, it remains plausible that the observed
IgG4 positivity reflects a non-specific effect of dense lympho-
plasmacytic chronic inflammation. Furthermore, our cohort
is clearly highly selected in those with advanced disease and
is not therefore directly comparable to studies of patients
with earlier disease that may or may not progress to trans-
plantation.
In conclusion, hilar IgG4 staining is apparent on detailed
immunohistochemical evaluation of liver grafts of patients
with PSC in approximately 50% of cases. Such patients,
particularly those with marked hilar IgG4+ staining, were
more likely to have dominant strictures and need for bili-
ary intervention. However, this in itself did not represent a
subgroup with worse clinical outcome. It remains the case
that understanding the drivers of IgG4 staining is still
incomplete, and at present, the routine histological evalua-
tion of peripheral IgG4 staining not clinically indicated.
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